As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue. While the proposals are going to be more painful for the drug industry, there are areas that bring heartburn to 340B providers.
U.S. Health and Human Services (HHS) Secretary Xavier Becerra met his Aug. 23 deadline to give the White House a plan to fight excessive drug prices, a White House official speaking on background said yesterday. The report will be published publicly in the coming weeks, the official said.
As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue. While the proposals are going to be more painful for the drug industry, there are areas that bring heartburn to 340B providers.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
